Affimed (NASDAQ:AFMD) Price Target Lowered to $4.00 at Stifel Nicolaus

Affimed (NASDAQ:AFMD) had its target price cut by research analysts at Stifel Nicolaus from $5.00 to $4.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 14.94% from the stock’s current price.

A number of other analysts also recently weighed in on AFMD. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Affimed Price Performance

Shares of AFMD opened at $3.48 on Friday. The company has a 50-day simple moving average of $3.49 and a two-hundred day simple moving average of $4.52. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. Affimed has a one year low of $2.92 and a one year high of $8.95.

Affimed (NASDAQ:AFMD) last released its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. Research analysts anticipate that Affimed will post -4.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Affimed

Large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Affimed during the 3rd quarter valued at about $44,000. Choreo LLC bought a new position in shares of Affimed in the second quarter worth approximately $54,000. FMR LLC lifted its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares in the last quarter. Intellectus Partners LLC grew its holdings in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.